IPP Bureau
Granules India receives ANDA approval for Trazodone Tablets
By IPP Bureau - August 11, 2024
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Merck's aarogya health program positively impacts communities in Patalganga
By IPP Bureau - August 11, 2024
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb
By IPP Bureau - August 11, 2024
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Allergan Aesthetics drives India’s potential in the global aesthetic market
By IPP Bureau - August 11, 2024
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr
By IPP Bureau - August 11, 2024
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years
By IPP Bureau - August 10, 2024
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
By IPP Bureau - August 10, 2024
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
By IPP Bureau - August 10, 2024
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
32 projects completed under PLI Scheme for promotion of domestic manufacturing of Critical KSMs/DIs and APIs
By IPP Bureau - August 10, 2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25
By IPP Bureau - August 09, 2024
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Atul Bioscience received EIR from USFDA for Ambernath facility
By IPP Bureau - August 09, 2024
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
CCRUM organises webinar on quality standards for healthcare delivery system in Unani Medicine
By IPP Bureau - August 08, 2024
Nearly 200 participants from 50 Unani Academia and Council participated
Jagsonpal Pharmaceuticals Q1 FY25 revenues at Rs. 61.4 Crores, 41% growth over Q4 FY24
By IPP Bureau - August 08, 2024
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
By IPP Bureau - August 08, 2024
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
